Hengrui Q3 Net Profit Jumps 89% as Revenue Rises 21%
Jiangsu Hengrui Pharmaceuticals reported Q3 2026 net profit of RMB2.46B, up 88.92% YoY, on revenue of RMB8.95B, up 20.55%.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Jiangsu Hengrui Pharmaceuticals posted revenue of RMB8.95B in the third quarter of 2026, up 20.55% year on year. Net profit reached RMB2.46B, a gain of 88.92% from a year earlier.
Over the first nine months of 2026, revenue came to RMB24.41B, up 5.26%, and net profit to RMB6.92B, up 20.38%. The figures are taken from a release distributed by Asian Corporate Newswire and carried by TradingView.
why it matters
Faster profit growth than revenue growth over nine months points to better margins or a richer product mix. Investors will watch regulatory approvals and milestones on GLP-1 assets, along with the Novo deal for HRS-1596 worth up to $2.6B.
market impact
Jiangsu Hengrui shares: strong results support interest in the company's stock
- Jiangsu Hengrui shares pressure up — faster third-quarter profit growth supports investor interest
tags
instruments
sources
- Jiangsu Hengrui Pharmaceuticals Co., Ltd. Q3 Profit +89% YoY; 9M Profit +20% — TradingView, 27 October 2026 at 10:49 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗